# US 2015/0174249 A1 · Composition for Patch Preparation Comprising Drug, Organic Solvent, Lipophilic Mass Base, and Powder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174249 A1
- Document ID: US20150174249A1
- Status: Published application
- Kind: A1
- Application number: 14/408,649
- Filed: 2013-06-18
- Published: 2015-06-25
- Earliest claimed: 2012-06-20
- Assignees: Medrx Co., Ltd.
- Applicants: Medrx Co., Ltd.
- Inventors: Hidetoshi Hamamoto; Katsuhiro Yamanaka; Takahiro Tanimoto
- Web page: https://patentgrep.com/patent/US20150174249A1

## CPC

- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/23: Calcitonins
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug.

## Claims

### Claim 1

A composition for a non-aqueous patch preparation comprising a drug, an organic solvent, a lipophilic mass base, and a powder.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the powder is insoluble both in the drug solution in the organic solvent and in the lipophilic mass base.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the powder is at least one selected from the group consisting of crystalline cellulose, anhydrous silicic acid, starch, carmellose, carmellose metal salt, kaolin, agar, carrageenan, pectin, powdered sugar, polyethylene powder, and polystyrene sulfonate.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the powder is crystalline cellulose.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the organic solvent comprises an ionic liquid.

### Claim 6 (depends on 5)

The composition according to claim 5, wherein the ionic liquid is an alkanolamine organic carboxylate.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein said organic carboxylic acid is a combination of a higher fatty acid and an organic carboxylic acid having 3 to 7 carbon atoms.

### Claim 8 (depends on 7)

The composition according to claim 7, wherein said higher fatty acid is a saturated or unsaturated fatty acid having 10 to 22 carbon atoms.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein said saturated or unsaturated fatty acid having 10 to 22 carbon atoms is at least one selected from the group consisting of decanoic acid, oleic acid, isostearic acid, and myristic acid.

### Claim 10 (depends on 7)

The composition according to claim 7, wherein said organic carboxylic acid having 3 to 7 carbon atoms is a carboxylic acid compound having a hydroxyl group and ketone group.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein said carboxylic acid compound having a hydroxyl group and a ketone group is at least one selected from the group consisting of lactic acid, levulinic acid, and salicylic acid.

### Claim 12 (depends on 6)

The composition according to claim 6, wherein said alkanolamine is at least one selected from the group consisting of triethanolamine, triisopropanolamine, and diisopropanolamine.

### Claim 13 (depends on 5)

The composition according to claim 5, wherein said ionic liquid is at least one selected from the group consisting of triethanolamine lactate, triisopropanolamine lactate, triethanolamine levulinate, diisopropanolamine levulinate, triisopropanolamine decanoate, triethanolamine salicylate, diisopropanolamine oleate, triethanolamine isostearate, diisopropanolamine isostearate, and diisopropanolamine myristate.

### Claim 14 (depends on 7)

The composition according to claim 7, wherein said ionic liquid of an alkanolamine salt of organic carboxylic acid having 3 to 7 carbon atoms is at least one selected from the group consisting of triethanolamine lactate, triisopropanolamine lactate, triethanolamine levulinate, diisopropanolamine levulinate, triethanolamine salicylate, and triisopropanolamine salicylate.

### Claim 15 (depends on 8)

The composition according to claim 8, wherein said ionic liquid of an alkanolamine salt of saturated or unsaturated fatty acid having 10 to 22 carbon atoms is at least one selected from the group consisting of triisopropanolamine decanoate, triethanolamine decanoate, diisopropanolamine decanoate, diisopropanolamine oleate, triethanolamine isostearate, diisopropanolamine isostearate, and diisopropanolamine myristate.

### Claim 16 (depends on 1)

The composition according to claim 1, wherein the elastomer of said lipophilic mass base is styrene-isoprene-styrene block copolymer.

### Claim 17 (depends on 1)

The composition according to claim 1, wherein said drug is selected from a small molecular medicinal compound, a protein medicine, an antigen peptide, or a nucleic acid derivative.
